I n recent years, American workplaces have focused on doing more with less by increasing the use of automation and requiring more productivity from workers. Thus, more than ever, a healthy work force is essential. Chronic diseases, especially those that are not well controlled, lead to increased business costs through lost time and productivity, lower quality of life for employees, and skyrocketing health costs for both businesses and workers.
Occupational health nurses are ideal professionals to create a win-win dynamic in their organizations by establishing programs that help employees effectively manage chronic diseases such as asthma. This article provides an overview on managing asthma in the workplace; reviews the pathophysiology, disease classifications, and current treatments; and presents a proposed asthma management plan for affected workers.
WHAT IS ASTHMA?
Asthma is a chronic inflammatory disease of the airways characterized by recurrent airway inflammation and resulting symptoms, including wheezing, shortness of breath, chest tightness, and coughing. Airways have increased sensitivity or responsiveness to a variety of ABOUT THE AUTHOR ABOUT THE SECTION EDITOR Dr. wachs isProfessor, East Tennessee State University, Johnson City, TN. NOVEMBER 2004, VOl.52, NO. 11 stimuli, such as dust and dust mites, cold air, cockroaches, mold, weather changes, pet dander, pollen, or smoke, and in women, the presence of menses (Centers for Disease Control and Prevention, 1999; National Asthma Education and Prevention Program [NAEPPl, 1997) .
Even though asthma is a chronic condition, it can have severe, life threatening exacerbations, which can occur in the workplace. Asthma can be a source of lost workdays as well as workdays with decreased productivity caused by fatigue, coughing, shortness of breath, or simple distraction from the task at hand. Employees can have asthma related to exposure to irritants and allergens in the workplace, or they can have asthma at baseline and bring this chronic illness into the work environment. The top 10 occupations for asthma prevalence are listed in the Sidebar. Regardless of the cause of asthma, management strategies are similar.
CATEGORIES OF WORK RELATED ASTHMA
There are two general categories of work related asthma: work aggravated asthma and occupational asthma (Youakim, 2(01) . Work aggravated asthma occurs in workers with a history of asthma who have recurrent symptomatic episodes during work. Common trigger mechanisms include exertion, exposure to cold temperatures, or exposure to inhaled irritants such as dust, fumes, or aerosols (Brooks, 1998) .
Occupational asthma can occur in workers with no history of preexisting' asthma; the disease develops as a result of workplace exposure. There are two subcategories of occupational asthma depending on the type of onset. The first type is reactive airway dysfunction syndrome (RADS), which develops from a one time, high intensity exposure to an irritant (see Table I ). In most cases, RADS will develop within 24 hours of the exposure.
The second type of occupational asthma, allergic occupational asthma, is more subtle and is the result of prolonged, but lower level, exposure to a substance in the workplace during a period of time ranging anywhere from weeks to as long as 30 years. Because of this extremely variable latency period, it may be difficult, if not impossible, to connect a worker's exposure to a particular agent with the resulting asthma symptoms.
Individuals with all types of asthma (work related and nonwork related) tend to have nonspecific bronchial hyperresponsiveness, which is a tendency to develop bronchospasm in response to nonspecific triggers such as cold air, exercise, or environmental agents (e.g., dust, smoke). Individuals with occupational asthma also display specific bronchial hyperresponsiveness when exposed to very low concentrations of the substance or substances to which they have become sensitized (Youakim, 2001) . Substances that have been implicated in allergic occupational asthma are listed in Table 2 .
ASTHMA PATHOPHYSIOLOGY
Asthma begins at the cellular level. When sensitizing antigens enter the airway, they are recognized by T cells. Some of the activated T cells die as a result of exposure to the antigen, but others develop into memory T cells. These cells are at the root of the inflammatory response that occurs when an individual is reexposed to the sensitizing antigen (NAEPP, 1997) .
The inflammatory response is prolonged or mediated when mast cells release histamines and leukotrienes.
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Histamine attaches to receptors in the large airways, while the leukotrienes attach to receptors in the small airways. Prostaglandins are then released, which potentiates histamine response (American Thoracic Society Workshop, 2003) . The result is what is normally considered an asthmatic response, episode, or attack. Common asthma signs and symptoms produced by this reaction are listed in Table 3 .
ASTHMA SEVERITY CLASSIFICATIONS
The National Institutes of Health's National Heart, Lung, and Blood Institute has developed a four step classification of asthma severity based on signs and symptoms before treatment (NAEPP, 1997 (NAEPP, ,2002 . The levels range from one (least severe) to four (most severe). Recommendations of the NAEPP's Expert Panel Report 2 are considered the gold standard in diagnosing, treating, and managing asthma (see Figure I ).
ASTHMA COSTS IN THE WORKPLACE
During the past 15 years, the number of individuals with asthma has nearly doubled. More than 14 million individuals, or approximately 5% of the population, have asthma (Williams, 2001) . The majority (66%) of these individuals are older than age 18 and thus are eligible to be in the work force. It is estimated that on an average day, more than 28,000 individuals visit their health care providers for treatment of asthma and related symptoms. Another 200 per hour enter emergency departments for care, and 53 per hour are hospitalized. In the United States, approximately 15 individuals die from asthma every day (Williams, 2001) .
A survey by the Employer Health Coalition found asthma was responsible for 3.4 lost workdays per worker with asthma per year (Reese, 2000) , resulting in a total of 14.5 million yearly absences of working adults (Stoloff, 2003) . Considering these numbers, and the fact that most people with asthma are of working age, the costs of asthma to both individuals and businesses are staggering: the National Institutes of Health estimates the direct costs for asthma care in 2004 will reach $16.1 billion: $4.6 billion in indirect costs such as lost earnings and reduced productivity and $11.5 billion in direct costs. These costs are projected to climb to at least $18 billion by 2020 (Leigh, 2002; National Heart, Lung, and Blood Institute, 2004; Williams, 2001) .
Between 5% and 25% of newly diagnosed asthma cases or exacerbations of previously existing asthma are linked to workers' exposure to workplace triggers. According to Leigh (2002) , this translates each year into $7.5 billion in direct costs (medical expenses) plus $3.8 billion in indirect costs (lost earnings and lost production). Moreover, Leigh noted these estimates were "conservative."
Poorly managed asthma leads to absenteeism, emergency room visits, hospitalizations, and even death. Further impacts include higher health care costs for businesses and lost productivity. Occupational health nurses are in a key position to help workers manage asthma effectively to reduce this economic impact.
(Adapted from American Thoracic Society Workshop, 2003; Youakim, 2001) . (American Thoracic Society Workshop 2003; Centers for Disease Control and Prevention, 1999) . Peak Flow Monitoring Education Factors critical to the success of PEF monitoring are that individuals with asthma are properly educated about PEF technique and that monitoring is consistent and ongoing. Occupational health nurses can augment the use of PEP monitoring for workers who have asthma by:
ASTHMA MANAGEMENT
The key to asthma management is the regulation and control of chronic airway inflammation. Secondary is managing associated bronchospasm. This is accomplished in three ways: • Monitoring lung function to detect decreases in exhaled flow rates before full blown exacerbations occur. • Properly administering quick relief or long term control medications. • Providing ongoing education and reinforcing best practices (NAEPP, 1997) .
Occupational health nurses are ideally suited to lead the way in all three of these areas, particularly with the unique opportunity occupational health nurses have to work with employees with asthma who are not acutely ill at the time of contact.
Monitoring Lung Function
The standard for regularly evaluating lung function is peak expiratory flow (PEF) monitoring, which also is abbreviated PEFR, in which the R stands for "rate." To use the peak flow meter, individuals take as deep a breath as possible, ideally to vital capacity, place the peak flow meter in their mouth, and give a short, forced exhalation. It often is easier for individuals to replicate this technique when it is described as the same breathing pattern used to blowout birthday candles. Generally, individuals "blow" three times and record the best result.
All individuals with asthma should know how to measure PEF, establish their personal best, and be able to measure PEF if symptoms worsen. Individuals with moderate to severe persistent asthma are encouraged to measure their PEF in the morning and evening, chart the results, and note any changes. A reading that is 80% of baseline (or predicted normal value, based on gender, height, and age) indicates mild obstruction; 50% to 80% of baseline indicates moderate obstruction; and less than 50% of baseline indicates severe obstruction (NAEPP, 1997) . Each individual's asthma action plan should list interventions if PEF drops to a certain level.
With PEF monitoring, individuals who have asthma can easily and regularly measure their lung function independently, taking more responsibility for self monitoring and care. PEF results are quantitative and reproducible, provide solid data on air flow, and indicate how individuals respond to initiation of or changes in treatment. PEF monitoring also can provide quantitative data on individuals' reactivity to environmental or occupational exposures when measurements are obtained at the start and end of the workday. Cowie (1997) examined PEF monitoring and found self report of symptoms to be unreliable as many individuals tend to underestimate the severity of their disease or underreport symptoms of impending exacerbations until the exacerbation is full blown. Cowie found the quantitative data from PEF monitoring provided important feedback for individuals with asthma. Study participants became more proactive in recognizing and managing impending exacerbations, and as a result, significantly decreased the need for urgent treatment. Step 4: Severe Persistent • Symptoms are present continually • Physical activity is limited • Exacerbations and nighttime symptoms occur frequently number of copyright free charts and worksheets that can be duplicated and used in the workplace).
• Monitoring environmental triggers and their impact on PEF readings of sensitive or symptomatic workers.
Proper Administration of Medications
Most individuals who have asthma need to learn about the appropriate use of the many medications currently available for controlling asthma. Asthma often is associated with the traditional pressurized metered dose inhaler (MOl), which can be misleading and create confusion regarding the action and indication for each inhaled medication for individuals with asthma. Currently, not only are inhalers used for different classes of medication, but there are also different devices that deliver asthma medication. In some cases, a combination of inhaled and oral medications may be indicated, which can add to the confusion.
Inhaled MedlcatlDn Del/very Devices
The device traditionally used to deliver asthma medication is the MDI. However, it is difficult to master proper technique; one representative study found 77% to 89% of 50 I clients made errors when demonstrating how they used their MDI (Larsen, 1994) .To make the technique easier to perform correctly, the MDI can be connected to a spacer or holding chamber that "holds" the appropriate dose until the user inhales so the user does not need to coordinate taking a breath and depressing the canister at just the right time. There has been a move away from MDIs with chlorofluorocarbon propellants to those that use a different mechanism or to powder inhalers that do
Step 3: Moderate Persistent • Symptoms are present daily • Daily use of inhaled short acting beta-2 agonist before optimal treatment • Exacerbations affect activity • Exacerbations are present two or more times per week and may last for days • Nighttime symptoms occur more than once per week
Step 2: Mild Persistent • Symptoms are present more than twice a week, but less than once a day • Exacerbations may affect activities • Nighttime symptoms are present two or more times per month
Step 1: Mild Interminent • Symptoms are present two orfewer times a week • No symptoms are present and peak expiratory flow rate is normal between exacerbations • Exacerbations are brief (a few hours to a few days); intensity of exacerbations may vary • Nighttime symptoms are present two or fewer times per month (National Asthma Education and Prevention Program, 1997) . not need propellant. This is a segment of asthma management poised for significant changes in the corning years.
RECOMMENDED ASTHMA MEDICATIONS
The following section provides an overview of the different types of medications currently used to manage asthma according to the most recent protocols published in the NAEPP's Expert Panel Report 2 in 1997 and updated in 2002. Table 4 lists quick relief and long term control medications for asthma, and Figure 2 illustrates asthma management medication guidelines based on disease severity classifications.
Quick Relief Medications
Beta-Z Agonist Bronchodilators. This group of quick relief asthma medications includes albuterol (Proventil
Long Term Control Medications (Taken Dally)
Corticosteroids (inhaled and systematic)
Long acting beta-2 agonists
Cromones
Leukotriene modifiers
Methylxanthines (inlimited cases)
and Ventolin), formoterol (Foradil), and pirbuterol (Maxair). These bronchodilators, which are often called "rescue" medications, act rapidly to relax the smooth muscle in the airways and reduce asthma symptoms. They are usually effective for 4 to 6 hours and can prevent and reverse exercise induced bronchospasm. Quick relief bronchodilators work best when they are used as needed rather than daily for mild asthma and acute exacerbations. If used daily to treat asthma, these medications can actually increase airway hyperresponsiveness over time, making this overuse particularly unwise. If an individual with asthma must use a short acting inhaler daily to treat symptoms or a decreased PEF, the underlying disease is not under control and a daily long term treatment medicine needs to be added to the regimen, the dose may need to be adjusted, or a different
Step 4: Severe Persistent • Daily inhaled steroid (high dose) PLUS long term control beta-2 agonist PLUS oral steroid (with repeated attempts to lower or reduce oral steroids) • As needed quick relief beta-2 agonist
Step 3: Moderate Persistent • Daily inhaled steroid (low to medium dose) OR • Inhaled steroid (low to medium dose) PLUS long term control beta-2 agonist • As needed quick relief beta-2 agonist
Step 2: Mild Persistent • Daily inhaled steroid (low dose) OR • Cromone • As needed quick relief beta-2 agonist
Step 1: MildIntermittent • No daily medications • As needed quick relief beta-2 agonist class of medication may need to be considered. With proper asthma control, individuals with asthma should not need more than one rescue MDI per month, and with optimum treatment and trigger avoidance, the MDI should last for a number of months.
Anticholinergics. This group of medication includes ipratropium (Atrovent) and combined ipratropiumalbuterol (Combivent). Ipratropium acts by cholinergic innervation to regulate airway smooth muscle tone. It should be used for quick relief of acute asthma episodes. Combivent combines two quick relief medications: one anticholinergic (ipratropium) and one beta-2 agonist (albuterol) so that airway spasm can be controlled through two different mechanisms for maximum effect.
Long Term Control Mldlcations
Beta-2 Agonist Bronchodilator. Salmeterol (Serevent) is a long term control beta-2 agonist bronchodilator that works in the same way as the quick relief beta-2 agonists but is intended to control asthma over the long term. This medication should be used daily in conjunction with inhaled anti-inflammatory medications. Long term beta-2 agonist medication generally is prescribed for individuals who have nocturnal asthma symptoms or exercise induced bronchospasm.
Properly used, the long term control beta-2 agonist will help prevent exacerbations but is not designed to treat an acute exacerbation. A key part of disease management is making sure individuals with asthma understand the difference between quick relief and long term control beta-2 agonists and the role each plays in asthma control.
Inhaled Corticosteroids. Long term inhaled corticosteroids include flunisolide (AeroBid), budesonide (Pulmicort), beclomethasone (Beclovent), and fluticasone (Flovent). Inhaled corticosteroids are considered the most effective long term control therapy currently available. When taken in appropriate doses, they produce a potent local effect while posing minimal risk for systemic or other adverse effects commonly associated with long term systemic corticosteroid use.
Daily use of inhaled corticosteroids provides effective control of asthma symptoms, including decreased airway hyperresponsiveness and inflammation, fewer severe exacerbations, improved lung function, and decreased need for quick relief medications. Again, correct inhalation techniques and appropriate, consistent daily dosing are crucial to the success of these medications. Individuals need to understand that long term' inhaled corticosteroids do not provide quick relief of asthma symptoms but are intended to prevent exacerbations by suppressing inflammatory response.
A popular combination of fluticasone (Flovent) and salmeterol (Serevent), called Advair Diskus, is an inhalation powder for daily, long term asthma management. This combination of medications is recommended for daily use in moderate and severe persistent asthma and reduces the number of inhalers needed, making it easier for individuals with asthma to follow their treatment plans. Systemic Corticosteroids. Methylprednisolone, prednisolone, and prednisone are long term control systemic corticosteroids that continue to be recommended for uncontrolled moderate to severe asthma (i.e., Step 3 and
Step 4 asthma). These medications are absorbed rapidly and work relatively quickly to reduce inflammation. Most individuals with asthma experience significant improvement within 24 hours after beginning treatment.
A short course of systemic corticosteroids is often the first step in long term asthma therapy to control inflammation quickly and effectively because a short course (called a "burst") of these medications has minimal side effects. In one study of individuals treated in an emergency department for asthma exacerbation, a single intramuscular dose of methylprednisolone administered at discharge was found to be a viable alternative to an 8 day tapering course of oral methylprednisolone (Lahn, 2004) .
Concerns about side effects from daily use of systemic corticosteroids for long term therapy are real. The benefits of steroid use such as improved respiratory status that allow individuals to more fully participate in daily activities, must be weighed against the potential side effects, which include Cushing's syndrome, osteoporosis, muscle weakness, and dermal thinning.
Cromones. Crornones, which include cromolyn sodium (Intal) and nedocrornil (Tilade), are inhaled, nonsteroidal anti-inflammatory drugs that work to stabilize mast cell breakdown, which is part of the inflammatory response. Cromones are particularly useful for individuals who need strong anti-inflammatory effects but have contraindications to corticosteroids or for individuals who do not want to take corticosteroids. Many individuals with asthma find these medications produce long term control; however, some individuals have no clinical response to cromones.
Leukotriene Modifiers. The newest category of long term asthma control medications, lekotriene modifiers are oral medications that include zafirlukast (Accolate), montelukast (Singulair), and zileuton (Zyflo). Leukotrienes are produced by inflammatory cells as part of the asthmatic response. These chemical mediators also recruit other inflammatory cells into the airways that increase symptoms such as mucous production. Leukotriene modifiers interfere with leukotriene activity; the most popular, montelukast and zafirlukast, block the leukotriene receptor sites. With leukotrienes' effects blocked, the inflammatory response is stopped at the outset. Individuals who take these medications usually have improved lung function, reduced use of quick relief medications, reduced use of inhaled corticosteroids in some cases, and fewer and less severe exacerbations.
Leukotriene modifiers are not automatically recommended for long term asthma control. Studies are currently being conducted to further define the role of these relatively new drugs. Data thus far (Ng, 2004) indicate leukotriene modifiers are no more effective than inhaled corticosteroids if the inhaled drugs are administered correctly. However, considering that at least 77% of individuals use inhalers incorrectly, in actual community use, oral medication may be more effective. On one hand, experts note leukotriene modifiers are much more expensive and increase the total costs of care (O'Connor, 2(03). On the other hand, these oral medications eliminate the dosage variability that can occur with improper inhaler technique. Individuals with asthma may find it much easier to take a pill, may prefer this approach to asthma management, and may be more likely to take one pill a day compared to multiple puffs from an inhaler. It is an area to monitor in the coming years as more research is published.
Methylxanthine Bronchodilators. For many years, methylxanthine bronchodilators such as theophylline were considered the standard for long term control and acute exacerbations. However, these mild to moderate bronchodilators, whose action is uncertain, are no longer considered front line medications. Instead, they are currently considered adjunct medications to beta-2 agonist and inhaled anti-inflammatory medications and are used primarily to treat nocturnal asthma. They should not be used automatically for acute exacerbations as they once were. All clients should try two to four puffs of a quick relief beta-2 agonist as needed for exacerbations, and if exacerbations persist, a short course of oral steroids may be needed to regain control of inflammation.
ROLE OF OCCUPATIONAL HEALTH NURSES

Developing Protocols
To enhance workplace asthma management, occupational health nurses, in collaboration with other members of the health care team, should develop written asthma management protocols. These can cover the use of medications including guidelines for workplace safety related to medications (e.g., medications such as first generation antihistamines, which may be used for allergies occurring concomitantly with asthma, that can cause drowsines), when to call emergency services, and guidelines on the use of inhalers or nebulizers in the workplace.
Occupational health nurses also should have an in house emergency protocol for treating severe asthma exacerbations. The NAEPP (1997) guidelines recommend the following steps for treating severe asthma exacerbations: • Administer high dose quick relief beta-2 agonist (albuterol) and anticholinergic (ipratropium) by nebulizer every 20 minutes or continuously for an hour. • Administer oxygen to keep oxygen saturation as measured by pulse oximetry > 90% (> 95% if worker also has heart disease) • Administer corticosteroids orally or intravenously • Reassess after 1 hour using PEF and continue therapy as above if peak flow or symptoms have not improved.
Providing Ongoing Workplace Education and Reinforcement
Positive outcomes reported by Kotses (1995) Each of these elements can save employers money, either through increased worker productivity or by reducing the use of costly health care resources. Given the amount of lost productivity and poor quality of life attributable to workplace asthma exacerbations, looking at asthma management proactively on the job makes sense. In general, the best course is ongoing treatment combined with education and easy access to self management tools. Some ways these can be accomplished include: • Developing and supporting an ongoing education and management plan for asthma that covers possible irritants and triggers in the workplace; proper use of medications; self management plans; and when, where, and how to seek help if a worker becomes short of breath while working as well as outside the workplace. • Establishing a flexible access "asthma information" center in the workplace. • Allowing flex time for asthma related health care visits (both in house nurse visits and consults with outside health care providers). • Encouraging a "do not wait" policy for consulting the occupational health nurse for an asthma exacerbation. • Supporting smoking cessation programs (and negotiating reimbursement for these programs and nicotine withdrawal medications in the company's health insurance plan). • Providing smoke free entrances at the workplace as well as smoke free work and break areas, and strictly enforcing the rules that keep these areas smoke free. • Supporting use of asthma medications in the workplace (make sure a "zero tolerance" workplace drug policy specifically excludes asthma and smoking cessation medication). • Developing partnerships with local asthma organizations.
• Ensuring employee access to adequate health care coverage for asthma care and disease management.
The Sidebar lists five key educational components health care providers should address jointly with clients. Heyman (1999) encourages developing a simple surveillance questionnaire to help identify occupational exposures as well as early symptoms of asthma. This type of questionnaire can be used as a starting place for an effective, evidence based, workplace asthma management program.
Advertising and promoting such a program is a key to its success. Workers need to know that education and treatment are available. Occupational health nurses should encourage employees to seek information and care sooner rather than later and ensure that there will be no punitive measures if workers seek care for symptoms during the workday.
Limiting Worker Exposure
The best way to reduce asthma exacerbations in the workplace over time is to control workers' exposures to substances that have been known to trigger asthma exacerbations. Longitudinal studies of workers with occupational asthma show asthma worsens with increased exposure to The Five Rs .,
The Five'Rs represent educational tasks health care providers and individuals with asthma need to address:
• Reach agreement ongoals. The goals of primary health care providers, occupational health nurses, and workers may not be the same; points of view need to be discussed and atreatment plan developed that reflects collaborative goals.
• Rehearse skills. Workers who have asthma need to learn how to use inhalers and peak flow meters properly and should be able to demonstrate proficiency with these devices. This will become increasingly important as more of the traditional metered dose inhalers with chlorofluorocarbon propellants are replaced with alternative inhaler devices such as the Diskus and various drypowder devices.
• Repeat messages. Every contact with a knowledgeable health care provider is an opportunity for individuals with asthma to repeat key messages about asthma knowledge and management, and to demonstrate psychomotor skills; occupational health nurses should be sure to ask.
• Reinforce. Asthma management must become an integral part of workers' everyday routine. Occupational health nurses can help achieve this goal, for example, by showing workers how to use an asthma diary and manage exacerbations effectively, Inaddition, occupational nurses can reinforce the concept that the worker is an individual who has asthmanotan "asthmatic" whose identity is defined by the disease.
• Review. Health care providers need to ask open ended questions to review and assess individuals' knowledge and to uncover any communication barriers or barriers to care that could affect the treatment plan. (Adapted fromStoia", 2003) .
the offending agent (Chan-Yeung, 1999) . While it may not be possible to remove all sources of irritants, some practical approaches include:
• Keeping ventilating systems clean and operational, and relative humidity constant (30% to 60%).
• Prohibiting smoking in the building and around entrances.
• Considering a policy on seemingly innocuous substances such as perfume or cologne and flowers, all of which can be potent triggers for individuals with asthma.
• Assessingjobs for their allergenic exposure and developing plans so sensitive workers are able to limit their exposure (Business and Health, 2002) .
ASTHMA MANAGEMENT PLAN IN ACTION
The Bank One Asthma Management Program is an example of a successful asthma management program in the workplace. This is a particularly interesting case because the workplace did not have traditional inhalational occupational exposures associated with asthma (Burton, 2(01) . Seventysix of 168 Bank One employees identified as having a history of pre-existing asthma volunteered to participate in the program. Employees attended five I hour classes scheduled at lunchtime that were taught by an asthma nurse specialist. The courses focused on recognizing triggers, the warning signs of an impending asthma attack, and how to use and care for equipment such as inhalers or peak flow meters. Attendees also received instruction on how to properly use medications, handle asthma emergencies, and keep an asthma diary as part of their asthma management plans. Employees who attended received incentives in the form of lunch during the sessions, a subscription to Asthma magazine, a tote bag filled with educational materials, a cold weather mask, an anti-allergen pillow protector, and an inhaler cover.
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The employees at Bank One achieved immediate and significant improvements in measures of asthma control, a decrease in barriers to enhancing knowledge and communication, and an increase in self efficacy. These benefits continued for 1 year after the program ended. The employer also benefited, as the cost to implement the program was low, and employees' improved asthma self care led to fewer absences and fewer days of lower productivity, as well as overall improved quality of life.
SUMMARY
Occupational health nurses are the ideal members of the workplace team to initiate disease management programs for chronic illnesses; asthma is just one disease for which occupational health nurses can make a difference. Employees win by improving their health and quality of life, having better control of a chronic health condition, simply feeling better, and using time off for vacation rather than sick days: Employers win by having healthier employees who are absent less often and more productive at work, and who cost the company less for their health care. Occupational health nurses are the key link in this cost saving, productivity enhancing chain. Being proactive in this disease management role clearly establishes occupational health nurses' value in their organization.
IN SUMMARY
2 The key to effective asthma management is control of airway inflammation. Other important elements include reducing exposure to triggers and controlling bronchospasm.
